BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence of human gastric juice protein. It has accumulated a substantial body of preclinical literature — primarily in rodent models — investigating effects on tissue healing, vascular function, and the nervous system. This overview specifically addresses bpc-157 research overview, and related research is indexed on PubMed.
Origin and Structure
BPC-157 was isolated from human gastric juice, which contains naturally occurring peptides involved in mucosal protection and healing. The synthetic version is a stable pentadecapeptide. It is gastric acid-stable — an unusual property for peptides — enabling oral delivery in animal models.
Documented Mechanisms in Preclinical Research
Nitric oxide system: Multiple studies report BPC-157 modulating NOS activity and NO signaling, a key mediator of vasodilation and tissue perfusion. Growth factor upregulation: Research reports VEGF and EGF receptor upregulation in healing tissue, potentially contributing to angiogenesis. Tendon healing: Some of the most replicated findings involve tendon-to-bone healing in rat models. Gastrointestinal protection: Extensive study in GI models — ethanol ulcers, NSAID injury, inflammatory bowel models.
Study Limitations
The vast majority of BPC-157 research is from animal models, predominantly from a single research group in Croatia. Human clinical trial data is essentially absent from the published record. Doses used in animal studies do not translate directly to humans without allometric scaling and safety studies. Publication bias is a concern in any preclinical literature.
See the full BPC-157 compound profile with PubMed citations and evidence-level assessment.
Where the Research Actually Comes From
The overwhelming majority of published BPC-157 research originates from a single research group led by Predrag Sikiric at the University of Zagreb School of Medicine in Croatia, publishing since the 1990s. This concentration matters for how the evidence should be weighed: a large body of preclinical literature from one lab, however consistent, is a narrower evidence base than the same volume of findings independently replicated across multiple unaffiliated research groups. Independent replication of Sikiric-group findings by other labs exists but is much more limited, which is a genuine and frequently under-discussed limitation of the BPC-157 literature as a whole.
No Completed Human Clinical Trials
As of this writing, BPC-157 has not completed peer-reviewed, placebo-controlled human clinical trials establishing safety or efficacy for any indication. All of the tendon, ligament, gut, and neurological healing findings referenced in community discussion and much of the published literature come from rodent and other animal models — not human data. Effects observed in animal models frequently do not translate to humans at comparable relative doses, due to differences in metabolism, gut physiology, and dose-scaling (allometric scaling), which is why the evidence-level distinction between “extensively studied in rodents” and “clinically proven in humans” is not a minor technicality — it is the central limitation of the current BPC-157 evidence base.
Regulatory Status Has Been Actively Shifting
BPC-157’s regulatory classification has changed multiple times in the past three years. The FDA placed it on the Category 2 bulk-substances list in September 2023 — the category for substances presenting significant safety concerns, which barred compounding pharmacies from legally preparing it. That listing was removed on April 22, 2026 after the underlying nomination was withdrawn, though BPC-157 was not moved to the permitted Category 1 list at that time, leaving it in a regulatory gray zone. On July 23-24, 2026, the FDA’s Pharmacy Compounding Advisory Committee formally reviewed BPC-157 for potential Category 1 reinstatement and voted 8-6 (with one abstention) to recommend it. That vote is a non-binding recommendation to the FDA, which has not yet issued a final decision as of this writing. Readers should treat BPC-157’s regulatory status as actively in flux and verify current standing directly against FDA.gov rather than any single article.
Frequently Asked Questions
Has BPC-157 been proven effective in humans?
No completed, peer-reviewed human clinical trial has established its safety or efficacy for any condition. The published evidence base is overwhelmingly preclinical (animal and in vitro) research.
Why does it matter that most research comes from one lab?
Independent replication across multiple unaffiliated research groups is a core pillar of scientific confidence. A large, internally consistent body of work from a single group is valuable but represents a narrower evidentiary base than the same findings independently confirmed elsewhere.
Is BPC-157 currently legal to compound into a prescription?
Its status has changed multiple times since 2023 and remains unsettled as of mid-2026 — a July 2026 FDA advisory committee recommended reinstating it to the permitted-compounding list, but this is a non-binding recommendation pending final FDA action. Current status should always be verified directly against FDA.gov.
Educational research reference only. BPC-157 is not an approved drug and not intended for human therapeutic use.